December 17, 2024

Food Recall Trends: Listeria, Salmonella, and E. coli Risks

Explore key insights from a 2-decade analysis of US food recalls, revealing alarming trends in foodborne illness outbreaks caused by Listeria, Salmonella, and E. coli, and the need for improved food safety measures.

Conexiant

December 16, 2024

Study Finds New Sexual Transmission Disease Risks

Review expands list of viruses persisting in human semen from 9 to 22.

Conexiant

December 12, 2024

FDA Monitoring Ocaliva for Liver Injury

Intercept Pharmaceuticals' Ocaliva drug under FDA scrutiny for potential liver injury in patients without severe scarring.

Reuters

December 11, 2024

Combo Induces HBsAg Loss in HBV

A recent study found that a combination therapy in chronic hepatitis B patients with virologic suppression showed promising results in achieving HBsAg loss, but emphasized the need for longer follow-up to assess durability and potential side effects.

Conexiant

November 27, 2024

Processed Foods Linked to Active Psoriasis: Study

French researchers in JAMA Dermatology linked high ultraprocessed food consumption to increased rates of psoriasis, emphasizing the need for further investigation.

Conexiant

November 26, 2024

SLD Subtypes Linked to HCC, Cirrhosis

A recent study sheds light on the long-term risks of cirrhosis and hepatocellular carcinoma (HCC) among subtypes of steatotic liver disease (SLD) in adults, emphasizing the impact of metabolic dysfunction and alcohol intake on disease progression.

Conexiant

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

August 14, 2024

U.S. Adults’ Exposure to 6 Potentially Hepatotoxic Botanicals

A recent study found that approximately 15.6 million U.S. adults may be using botanicals with known liver toxicity, raising concerns about potential hepatotoxic risks and the lack of regulatory oversight.

Conexiant

November 01, 2024

Novo's Weight-Loss Drug Improves Liver Fibrosis in Late-Stage Trial

Novo Nordisk's latest trial reveals positive effects of weight-loss drug on liver health, pointing to potential benefits beyond weight management. #LiverHealth #Semaglutide

Reuters